Acro Biomedical (ACBM) Long-Term Deferred Tax (2018 - 2025)

Acro Biomedical has reported Long-Term Deferred Tax for 7 years, with the latest figure at $6.9 million in Q4 2025.

• On a quarterly basis, Long-Term Deferred Tax changed 0.28% year-over-year to $6.9 million in Q4 2025; TTM through Dec 2025 was $6.9 million, a 0.28% change from a year earlier, with the FY2025 full-year figure at $6.9 million, changed 0.28% from the prior year.
• Long-Term Deferred Tax was $6.9 million for Q4 2025 at Acro Biomedical, roughly flat from $6.9 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $6.9 million in Q4 2025, with the low at $76233.0 in Q2 2021.
• Average Long-Term Deferred Tax over 5 years is $3.9 million, with a median of $5.0 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Long-Term Deferred Tax surged 198.1% in 2022, then gained 0.12% in 2024.
• Over 5 years, Long-Term Deferred Tax stood at $1.7 million in 2021, then soared by 198.1% to $5.0 million in 2022, then soared by 36.87% to $6.9 million in 2023, then grew by 0.12% to $6.9 million in 2024, then gained by 0.28% to $6.9 million in 2025.
• The last three Long-Term Deferred Tax figures came in at $6.9 million (Q4 2025), $6.9 million (Q4 2024), and $6.9 million (Q4 2023), per Business Quant data.